Related content

Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

By van Kerrebroeck P.   Jardin A.   van Cangh P.   Laval K.U.   The ALFORTI Study Group  

European Urology, Vol. 41, Iss. 1, 2002-01 ,pp. : 54-61

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial 1

By Roehrborn C.G.   for the ALFUS STUDY GROUP  

Urology, Vol. 58, Iss. 6, 2001-12 ,pp. : 953-959

Elsevier

Access to resources Recommend Favorite

Treatment of men with minimally symptomatic benign prostatic hyperplasia-PRO: the argument in favor

By Marks L.S.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 781-783

Elsevier

Access to resources Recommend Favorite

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results

By Lukacs B.   Leplegrave ge A.   Thibault P.   Jardin A.  

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 731-740

Elsevier

Access to resources Recommend Favorite

Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up

By Lam J.S.   Romas N.A.   Lowe F.C.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 354-358

Elsevier

Access to resources Recommend Favorite